Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

3期 进行中（已停止招募） NCT04656652

摘要

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.

Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel

From randomization until disease progression or death (whichever occurs first), up to approximately 27 months · months

Overall Survival (OS) Following DS-1062a Versus Docetaxel

From randomization until date of death due to any cause, up to to approximately 38 months · months

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
• Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
• Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
• Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
• A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC

全部试验